Valuation gap in plain sight
Although GE HealthCare Technologies (GEHC) and Stryker Corp (SYK) operate in the same Healthcare Equipment & Supplies sector and serve similar hospital budget cycles, investors are pricing the two very differently. As of Sep 16, 12:34 PM EDT the last traded prices were $63.72 for GEHC and $288.27 for SYK, reflecting market capitalizations of $28.94B and $107.98B respectively. The core investment thesis for a pairs trade is that this valuation spread is larger than fundamentals justify and has scope to narrow.
Snapshot of key metrics
| Metric | GEHC | SYK | Edge |
|---|---|---|---|
| Price (Sep 16, 12:34 PM EDT) | $63.72 | $288.27 | — |
| Market Cap | $28.94B | $107.98B | — |
| P/E (LTM) | 14.5x | 29.6x | GEHC |
| P/E (Fwd) | 12.9x | 18.6x | GEHC |
| EV/EBITDA | 10.5x | 16.6x | GEHC |
| Price/Book | 2.6x | 4.6x | GEHC |
| FCF Yield | 5.5% | 4.3% | GEHC |
| Fair Value Upside | +25.4% → $79.93 | +10.9% → $319.71 | GEHC |
| Analyst Upside | 29.5% | 31.4% | ≈ Tie |
Why SYK commands a premium
Stryker’s valuation premium is supported by a set of high-quality operational metrics. It posts a perfect Piotroski score of 9, signalling robust financial health. Its gross margin sits near 65%, well above GEHC’s roughly 40%, reflecting the pricing power tied to surgical implants and instruments. Stryker’s revenue compound annual growth rate for 2021–2025 is approximately 10%, versus GEHC’s roughly 4%, positioning SYK as the faster top-line grower. Return on invested capital (ROIC) is 13.3% at SYK compared with 10.7% for GEHC, indicating stronger capital efficiency. Additionally, SYK has raised its dividend 16 consecutive times, while GEHC has raised its dividend 3 times, which can influence demand from income-focused investors.
All of these attributes justify a quality premium. The central question for a relative-value investor, however, is whether SYK’s near-30x LTM earnings multiple is commensurate with roughly 1.6x the ROIC and about 2.5x the revenue growth of GEHC. The analysis presented argues that the multiple differential is excessive relative to the operational gap.
GEHC’s undervalued levers
Support for a GEHC re-rating comes from several observable factors. The stock’s relative strength index (RSI) sits in oversold territory after a year-to-date decline of -22.84%, suggesting technical exhaustion. Management has signalled confidence through aggressive share buybacks and three consecutive dividend increases. GEHC generates the higher free cash flow yield of the pair at 5.5%, and is returning capital to shareholders. While GEHC’s debt-to-equity ratio of 96% is higher than SYK’s 64%, that capital structure largely reflects its post spin-off configuration rather than operational distress; interest coverage appears manageable against reported EBITDA of $3.64B. That said, 13 analysts have revised earnings downward for the upcoming period, which is identified as the primary downside risk to the thesis.
Pairs trade construction and rationale
A pairs trade seeks to be market-neutral so profits derive from convergence in the valuation spread rather than from broad market moves. The directional setup proposed is long GEHC and short SYK, with the expectation that GEHC’s deeper discount - implied fair-value upside of +25.4% to $79.93 versus SYK’s +10.9% to $319.71 - provides room for mean reversion.
Dollar-neutral example:
- Allocate $100,000 to long GEHC - roughly 1,570 shares at $63.72.
- Short $100,000 of SYK - roughly 347 shares at $288.27.
This construction is intended to neutralize broad market exposure so that profit and loss reflect the performance of the spread.
Beta adjustment (optional): GEHC beta is 0.82 and SYK beta is 0.77, which are close. For a stricter beta-neutral posture, scale the SYK short by (0.82/0.77) ≈ 1.065x.
Catalysts that could close the gap
- GEHC delivers an earnings beat and raises guidance, prompting a re-rating.
- SYK experiences a disappointment on surgical volumes or reports integration costs that compress its multiple.
- Sector rotation that favors value-oriented healthcare names over higher-growth benchmarks could also shrink the spread.
Risk management
Implement stop-loss discipline with an explicit trigger: if the P/E spread widens beyond 20x - meaning SYK trades at more than approximately 2.1x GEHC’s multiple - reassess the position. Such a move could indicate the market is pricing in a structural deterioration at GEHC not yet visible in the financials.
Bull and bear cases, summarized
| GEHC (Long) | SYK (Short) | |
|---|---|---|
| Bull | Cheapest in class, active buybacks, 25% upside to fair value | If SYK’s premium compresses, the short benefits |
| Bear | Earnings revisions and higher leverage | SYK’s Piotroski-9 quality makes sudden de-rating less likely |
Bottom line
From traditional valuation metrics, GEHC appears to offer stronger value. Stryker merits a quality premium, but at 29.6x LTM earnings versus GEHC’s 14.5x the premium looks stretched. A market-neutral pairs trade buying GEHC and shorting SYK captures this divergence without requiring a directional bet on the broader healthcare sector; returns depend on relative performance and the valuation gap narrowing.